Study Results from Tianjin Medical University Broaden Understanding of Clinical Trials and Studies (A Pilot Study on EGFR-Targeted Molecular Imaging of PET/CT With C-11-PD153035 in Human Gliomas)
By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Clinical Research have been presented. According to news reporting originating from Tianjin, People's Republic of China, by NewsRx correspondents, research stated, "C-11-PD153035, a potent and specific ATP-competitive tyrosine kinase inhibitor (TKI) of the EGF receptor, has been developed for PET imaging of epidermal growth factor receptor (EGFR) in lung cancer. The objective of the present study was to investigate the relationship of the accumulation of C-11-PD153035 and the EGFR expression level in human gliomas and to explore whether C-11-PD153035 can be used in the molecular imaging of glioma with EGFR overexpression."
Our news editors obtained a quote from the research from Tianjin Medical University, "Eleven patients with histopathologically proven gliomas underwent C-11-PD153035 PET/CT examination before surgery. Combining MRI with the C-11-PD153035 PET/CT image, 2 specimens from different C-11-PD153035 uptake regions of each tumor and adjacent normal brain tissue were selected as the biopsy targets through the stereotactic technique. The radioactivity concentrations were analyzed as the mathematical maximum standardized uptake value (SUVmax) in region of interest (ROI). The EGFR expression in the biopsied tissues was analyzed by immunohistochemical staining (IHC) and western blotting. The SUVmax/WM (C-11-PD153035 uptake in the white matter of the contralateral normal hemisphere) ratio was used to indicate the EGFR expression level in the ROI in PET/CT, and it was correlated with the EGFR expression detected by IHC and western blot analysis. The results demonstrated that 6 of the 8 patients with glioblastoma (GBM) were obviously visualized by C-11-PD153035 PET/CT, whereas 2 patients with GBM, 1 with anaplastic astrocytoma, and 2 with oligodendroglioma did not show significant C-11-PD153035 uptake. There were positive correlations between the SUVmax/WM and the results of IHC (r = 0.955, P< 0.01) and western blotting(r = 0.889, P< 0.010)."
According to the news editors, the research concluded: "Our preliminary findings suggest that C-11-PD153035 PET/CT is a promising method for the EGFR-targeted molecular imaging of human GBM, which may be translated into the clinic to select the appropriate population of patients for EGFR-targeted therapy and to assess the early targeted therapeutic response of malignant gliomas."
For more information on this research see: A Pilot Study on EGFR-Targeted Molecular Imaging of PET/CT With C-11-PD153035 in Human Gliomas. Clinical Nuclear Medicine, 2014;39(1):E20-E26. Clinical Nuclear Medicine can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA (see also Clinical Research).
The news editors report that additional information may be obtained by contacting J.K. Sun, Tianjin Med Univ, General Hospital, Dept. of Nucl Med, Tianjin, People's Republic of China. Additional authors for this research include L. Cai, K. Zhang, A.L. Zhang, P.Y. Pu, W.D. Yang and S. Gao.
Keywords for this news article include: Asia, Tianjin, Nanotechnology, Protein Kinases, Clinical Research, Membrane Proteins, Molecular Imaging, Phosphotransferases, Emerging Technologies, People's Republic of China, Clinical Trials and Studies, Epidermal Growth Factor Receptor, Receptor Protein-Tyrosine Kinases, Gastrointestinal Hormone Receptors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC